|Table of Contents|

The pattern of tumor regression after neoadjuvant chemotherapy for HER-2 positive invasive breast cancer and its influencing factors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 02
Page:
226-229
Research Field:
Publishing date:

Info

Title:
The pattern of tumor regression after neoadjuvant chemotherapy for HER-2 positive invasive breast cancer and its influencing factors
Author(s):
YANG Li1; HE Jianxin1; 2; ZHANG Chunxia1; MA Qiang1
1.General Surgery,Beijing Shunyi Hospital,Beijing 101300,China；2.General Surgery,Horqin Left Middle Banner People's Hospital,Inner Mongolia Tongliao 029399,China.
Keywords:
invasive breast cancer; neoadjuvant chemotherapy; human epidermal growth factor receptor 2; tumor regression pattern; concentric shrinkage mode; trastuzumab
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2022.02.010
Abstract:
Objective：To understand the pattern of tumor regression after neoadjuvant chemotherapy(NCT) for human epidermal growth factor receptor 2 (HER-2) positive invasive breast cancer (IBC) and to analyze its influencing factors.Methods:The clinicopathological data of 63 patients with HER-2-positive IBC who underwent NCT were retrospectively analyzed.According to the pathological residual tumor to judge the pattern of tumor regression,it was divided into concentric shrinkage mode(CSM) and non-concentric shrinkage mode(NCSM).The influencing factors related to the tumor regression pattern were analyzed.Results:Concentric shrinkage mode（CSM） was the predominant pattern in our study (65.08%，41/63).Univariate analysis:There was significant difference in the incidence of CSM among different tumor T stages before NCT,HER-2 expression level before NCT and whether combined with trastuzumab treatment groups (P＜0.05).There was no significant difference for tumor regression pattern among different ages,body mass index,axillary lymph node metastasis status before NCT,HR and Ki67 expression groups(P＞0.05).Multivariate analysis showed that the incidence of CSM in T2 group before NCT was higher than that in T3 group（OR=10.542，P=0.002）.The incidence of CSM was higher in the patient who treated with the NCT combined with trastuzumab group（OR=0.190，P=0.031）.There was no significant difference in different HER-2 expression groups for tumor regression pattern(P＞0.05).Conclusion:For patients with HER-2 positive IBC who want to have breast-conserving surgery after NCT,especially those with larger tumor,preoperative examination should be strengthened to assess the scope of residual tumors and choose the treatment combine trastuzumab targeted therapy to reduce the risk of local recurrence.

References:

［1］BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2018,68(6):394-424.
［2］中国抗癌协会专业委员会.中国抗癌协会乳腺癌诊疗指南与规范（2019年版）［J］.中国癌症杂志,2019,29(8):609-680. Professional Committee of China Anti Cancer Association.Breast cancer diagnosis and treatment guidelines and specifications of China Anti Cancer Association (2019 edition) ［J］.China Cancer Journal,2019,29(8):609-680.
［3］FISHER B,BRYANT J,WOLMARK N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer［J］.Journal of Clinical Oncology,1998,16(8):2672-2685.
［4］中国乳腺癌新辅助治疗专家组.中国乳腺癌新辅助治疗专家共识［J］.中国癌症杂志，2019,29(5):390-400. Chinese Expert Group on New Adjuvant Therapy for Breast Cancer.Consensus of Chinese experts on new adjuvant therapy for breast cancer ［J］.Chinese Journal of Cancer,2019,29（5):390-400.
［5］LING DC,SUTERA PA,IARROBINO NA,et al.Is multifocal regression a risk factor for ipsilateral breast tumor recurrence in the modern era after neoadjuvant chemotherapy and breast conservation therapy［J］.International Journal of Radiation Oncology Biology Physics,2019,104(4):869-876.
［6］SAW S,LIM J,LIM SH,et al.Patterns of relapse after neoadjuvant chemotherapy in breast cancer:implications for surveillance in clinical practice［J］.Breast Cancer Research and Treatment,2019,177(1):197-206.
［7］CLARK BZ,ONISKO A,ASSYLBEKOVA B,et al.Breast cancer global tumor biomarkers:a quality assurance study of intratumoral heterogeneity［J］.Modern Pathology,2019,32(3):354-366.
［8］MUFTAH AA,ALESKANDARANY MA,AL-KAABI MM,et al.Ki67 expression in invasive breast cancer:the use of tissue microarrays compared with whole tissue sections［J］.Breast Cancer Research and Treatment,2017,164(2):341-348.
［9］杨涛,张朝蓬,孙翔宇,等.病理三维重建研究新辅助化疗后乳腺原发肿瘤的退缩模式［J］.中华肿瘤杂志,2016,38(4):270-276. YANG T,ZHANG CP,SUN XY,et al.Three dimensional reconstruction of pathology to study the regression mode of primary breast cancer after neoadjuvant chemotherapy ［J］.Chinese Journal of Cancer,2016,38（4):270-276.
［10］VAN MAAREN MC,DE MUNCK L,STROBBE LJA,et al.Ten-year recurrence rates for breast cancer subtypes in the Netherlands:A large population-based study［J］.International Journal of Cancer,2019,144(2):263-272.
［11］GIANNI L,PIENKOWSKI T,IM YH,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer（NeoSphere):a randomised multicentre,open-label,phase 2 trial［J］.Lancet Oncology,2012,13(1):25-32.
［12］MAMOUNAS EP,ANDERSON SJ,DIGNAM JJ,et al.Predictors of locoregional recurrence after neoadjuvant chemotherapy:results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27［J］.Journal of Clinical Oncology,2012,30(32):3960-3966.
［13］MIEOG JSD,VAN DER HAGE JA,VAN DE VELDE CJH.Neoadjuvant chemotherapy for operable breast cancer［J］.British Journal of Surgery:Incorporating European Journal of Surgery and Swiss Surgery,2007,94(10):1189-1200.
［14］Early Breast Cancer Trialists' Collaborative Group（EBCTCG).Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer:Meta-analysis of individual patient data from ten randomised trials［J］.Lancet Oncology,2018,19(1):27-39.
［15］杨涛,张朝蓬,刘广,等.MRI三维评价乳腺癌新辅助化疗后残余肿瘤范围的准确性［J］.中华外科杂志,2015,53(4):280-284. YANG T,ZHANG CP,LIU G,et al.Accuracy of MRI in three-dimensional evaluation of residual tumor range after neoadjuvant chemotherapy for breast cancer ［J］.Chinese Journal of Surgery,2015,53（4):280-284.
［16］徐乘骏,张朝蓬,邱恒,等.分子分型对乳腺癌新辅助化疗后肿瘤退缩模式的影响［J］.中国肿瘤临床,2018,45(17):894-897. XU CJ,ZHANG CP,QIU H,et al.The effect of molecular typing on the pattern of tumor regression after neoadjuvant chemotherapy for breast cancer ［J］.Chinese Cancer Clinic,2018,45（17):894-897.
［17］SCHAEFGEN B,MATI M,SINN HP,et al.Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response［J］.Annals of Surgical Oncology,2016,23(3):789-795.
［18］GU YL,PAN SM,REN J,et al.Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy:a meta-analysis［J］.Clinical Breast Cancer,2017,17(4):245-255.
［19］周昊,陈祖锦,李云,等.腋窝淋巴结阳性乳腺癌新辅助化疗后腋窝治疗选择的研究［J］.中国肿瘤临床,2019,46(5):247-251. ZHOU H,CHEN ZJ,LI Y,et al.Axillary treatment after neoadjuvant chemotherapy for axillary lymph node positive breast cancer ［J］.Chinese Cancer Clinic,2019,46（5):247-251.
［20］方依寒，赵毅.乳腺癌新辅助化疗后腋窝淋巴结转移综合预测模型的建立［J］.现代肿瘤医学,2020,28(1):53-57. FANG YH，ZHAO Y.Establishment of a comprehensive prediction model for axillary lymph node metastasis after neoadjuvant chemotherapy［J］.Modern Oncology,2020,28(1):53-57.
［21］YOSHIDA A,HAYASHI N,SUZUKI K,et al.Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer［J］.Journal of Surgical Oncology,2017,116(8):1021-1028.
［22］VON MINCKWITZ G,HUANG CS,MANO MS,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer［J］.New England Journal of Medicine,2019,380(7):617-628.
［23］HURVITZ SA,MARTIN M,JUNG KH,et al.Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer:Three-year outcomes from the phase III KRISTINE study［J］.Journal of Clinical Oncology,2019,37(25):2206-2216.

Memo

Memo:
-
Last Update: 1900-01-01